179 related articles for article (PubMed ID: 15282667)
21. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
22. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
[TBL] [Abstract][Full Text] [Related]
23. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation.
Chen CC; Lee KD; Gau JP; Yu YB; You JY; Lee SC; Hsu HC; Chau WK; Ho CH
Ann Hematol; 2005 Oct; 84(10):675-80. PubMed ID: 16007424
[TBL] [Abstract][Full Text] [Related]
24. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
25. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
[TBL] [Abstract][Full Text] [Related]
26. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322
[TBL] [Abstract][Full Text] [Related]
27. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
[TBL] [Abstract][Full Text] [Related]
28. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
[TBL] [Abstract][Full Text] [Related]
29. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
30. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
31. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
Boffa MB; Koschinsky ML
Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
[TBL] [Abstract][Full Text] [Related]
32. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
Ladenvall C; Gils A; Jood K; Blomstrand C; Declerck PJ; Jern C
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):955-62. PubMed ID: 17272741
[TBL] [Abstract][Full Text] [Related]
33. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
Karakurt F; Gumus II; Bavbek N; Kargili A; Koca C; Selcoki Y; Ozbek M; Kosar A; Akcay A
Gynecol Endocrinol; 2008 Sep; 24(9):491-7. PubMed ID: 18958767
[TBL] [Abstract][Full Text] [Related]
34. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.
Kim PY; Foley J; Hsu G; Kim PY; Nesheim ME
Anal Biochem; 2008 Jan; 372(1):32-40. PubMed ID: 17967438
[TBL] [Abstract][Full Text] [Related]
35. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.
Van Thiel DH; George M; Fareed J
Thromb Haemost; 2001 Apr; 85(4):667-70. PubMed ID: 11341503
[TBL] [Abstract][Full Text] [Related]
36. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study.
Undén AL; Elofsson S; Brismar K
Clin Endocrinol (Oxf); 2005 Jul; 63(1):94-102. PubMed ID: 15963068
[TBL] [Abstract][Full Text] [Related]
37. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
38. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy.
Watanabe T; Minakami H; Sakata Y; Matsubara S; Sato I; Suzuki M
Gynecol Obstet Invest; 2004; 58(1):19-21. PubMed ID: 15004439
[TBL] [Abstract][Full Text] [Related]
39. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers.
Morange PE; Renucci JF; Charles MA; Aillaud MF; Giraud F; Grimaux M; Juhan-Vague I
Thromb Haemost; 2001 Jun; 85(6):999-1003. PubMed ID: 11434709
[TBL] [Abstract][Full Text] [Related]
40. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
Stasko J; Hudecek J; Kubisz P
Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]